Healthcare Analysts discuss the emerging treatment options for high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) (relevant companies ENGN CGON JNJ IBRX TARA URGN) on an Analyst/Industry conference call to be held on September 18.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- enGene price target lowered to $18 from $19 at Morgan Stanley
- Buy Rating for enGene Holdings: Strategic Positioning and Competitive Edge in NMIBC Market
- enGene Holdings Reports Q3 2025 Results and Milestones
- enGene Holdings Achieves Key Milestone in LEGEND Trial and Secures RMAT Designation
- enGene reports Q3 EPS 57c vs. 32c last year